Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative
- PMID: 24882105
- PMCID: PMC4079326
- DOI: 10.1021/jm5006572
Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative
Abstract
Production of β-lactamases (BLs) is the most widespread resistance mechanism adopted by bacteria to fight β-lactam antibiotics. The substrate spectrum of BLs has become increasingly broad, posing a serious health problem. Thus, there is an urgent need for novel BL inhibitors. Boronic acid transition-state analogues are able to reverse the resistance conferred by class A and C BLs. We describe a boronic acid analogue possessing interesting and potent broad-spectrum activity vs class A and C serine-based BLs. Starting from benzo(b)thiophene-2-boronic acid (BZBTH2B), a nanomolar non-β-lactam inhibitor of AmpC that can potentiate the activity of a third-generation cephalosporin against AmpC-producing resistant bacteria, we designed a novel broad-spectrum nanomolar inhibitor of class A and C BLs. Structure-based drug design (SBDD), synthesis, enzymology data, and X-ray crystallography results are discussed. We clarified the inhibitor binding geometry responsible for broad-spectrum activity vs serine-active BLs using double mutant thermodynamic cycle studies.
Figures






References
-
- Bebrone C.; Lassaux P.; Vercheval L.; Sohier J. S.; Jehaes A.; Sauvage E.; Galleni M. Current challenges in antimicrobial chemotherapy: focus on beta-lactamase inhibition. Drugs 2010, 706651–679. - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical